Search

Displaying results 1151 - 1160 of 6198 in total
  1. Drug

    Finafloxacin

    go.drugbank.com/drugs/DB09047
    ApprovedWithdrawn

    Finafloxacin is marketed by Novartis under the brand Xtoro™, and was approved by the FDA in December 2014. … Finafloxacin is a fluoroquinolone antibiotic indicated in the treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus.

  2. Drug

    Exemestane

    go.drugbank.com/drugs/DB00990
    ApprovedInvestigational

    Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal

  3. Drug

    Tebipenem pivoxil

    go.drugbank.com/drugs/DB16840
    Approved

    Tebipenem pivoxil is an orally administered prodrug of tebipenem, a carbapenem antibacterial that kills bacteria by binding essential penicillin-binding proteins and disrupting cell wall biosynthesis. … [L57979,L57980] It retains activity against many extended-spectrum beta-lactamase producers but not against organisms producing serine or metallo-carbapenemases.

  4. Drug

    Acipimox

    go.drugbank.com/drugs/DB09055
    ApprovedInvestigational

    Flushing can be reduced by taking aspirin 20-30 min before taking Acipimox. High doses can cause disorders of liver function, impair glucose tolerance and precipitate gout. … Long-term administration is associated with reduced mortality, but unwanted effects limit its clinical use.

  5. Drug

    Citric acid

    go.drugbank.com/drugs/DB04272
    ApprovedInvestigationalNutraceuticalVet approved

    It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium-chelating ability. … Citric acid is one of the active ingredients in Phexxi, a non-hormonal contraceptive agent that was approved by the FDA on May 2020.

    Mixtures: Up and Up Antacid and Pain Relief, U-Lite Effervescent Granules
  6. Drug

    Ribociclib

    go.drugbank.com/drugs/DB11730
    ApprovedInvestigational

    These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Ribociclib was approved by the FDA in March 2017 under the brand name Kisqali. … Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6).

  7. Drug

    rhThrombin

    go.drugbank.com/drugs/DB04923
    ApprovedWithdrawn

    The production of recombinant proteins is not dependent on the availability of blood from animals or human donors and can be scaled-up to meet market demand. … rhThrombin (recombinant human thrombin) is being developed by ZymoGenetics, Inc. as a general aid to achieving hemostasis during surgery.

  8. Drug

    Viltolarsen

    go.drugbank.com/drugs/DB15005
    ApprovedInvestigational

    [A218161, A218166, A218171, A218176, A218181, A218191, L15526] These shortened forms of dystrophin can restore partial muscle function and slow the progression of DMD. … Duchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder characterized by a lack of functional dystrophin protein, which leads to progressive ambulatory, pulmonary, and cardiac function

  9. Drug

    Elafibranor

    go.drugbank.com/drugs/DB05187
    ApprovedInvestigational

    [L50773] The drug was also approved by the EMA on September 23, 2024.[L51878] … [L50768] On June 10, 2024, elafibranor was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis (PBC).

  10. Drug

    Tofacitinib

    go.drugbank.com/drugs/DB08895
    ApprovedInvestigational

    Tofacitinib is marketed under the brand name Xeljanz by Pfizer. … Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function.